Purpose of the Study
====================

The objective of this study is to identify low frequency mutations in HIV-1C that cannot be detected by standard genotyping. We analysed samples from the Tshepo cohort in Botswana. Tshepo is an open-label, unblinded, randomised 3 × 2 × 2 factorial design study comparing 1) the rate of development and specific types of drug resistance mutational patterns among HIV-1C-infected adults treated with 6 initial HAART regimens; (2) the tolerability and efficacy of these HAART regimens; (3) evaluation of the When to Start HAART question as patients are initiated on HAART in two different baseline CD4+ cell count strata; and (4) comparing the short- and long-term effectiveness of two operational adherence strategies.

Methods
=======

Methodology involved quantification of the proviral load and multiple PCR with a single copy as a template followed by direct sequencing. Bulk sequencing was also carried out for each patient per time point.

Summary of Results
==================

Of the patients who had been enrolled in the study for at least one year, had longitudinal samples at every two month visit and had failed the first-line therapy, failed therapy, 30% of them showed no drug resistance mutations prior to the point of virological failureby single genome sequencing. Single genome sequencing revealed drug resistance mutations for the remaining 70% of the patients before virological failure was experienced.

Conclusion
==========

Single genome sequencing allows for the detection of low frequency mutation below the threshold of 30% for bulk sequencing, allows early detection of these mutations for some samples and in addition can detect mutations otherwise missed by conventional methods of detection
